GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Current Deferred Revenue

Frontage Holdings (HKSE:01521) Current Deferred Revenue : HK$0 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Frontage Holdings's current deferred revenue for the quarter that ended in Dec. 2023 was HK$0 Mil.

Frontage Holdings Current Deferred Revenue Historical Data

The historical data trend for Frontage Holdings's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Current Deferred Revenue Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial - - - - -

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Frontage Holdings Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Frontage Holdings (HKSE:01521) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Current Deferred Revenue
Comparable Companies
HKSE:02257 HKSE:01167 HKSE:01477 HKSE:02179 HKSE:02616 HKSE:01244 HKSE:01873 HKSE:06622 HKSE:02171 HKSE:02496 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
FGHQF:USA
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Website
https://www.frontagelab.com
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines